Identification

Name
Rasagiline
Accession Number
DB01367  (EXPT02758)
Type
Small Molecule
Groups
Approved
Description

Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Structure
Thumb
Synonyms
  • (1R)-N-Propargylindan-1-amine
  • (R)-Indan-1-yl-prop-2-ynyl-amine
  • (R)-N-2-Propynyl-1-indanamine
  • RAS
External IDs
AGN-1135
Product Ingredients
IngredientUNIICASInChI Key
Rasagiline mesylateLH8C2JI290161735-79-1JDBJJCWRXSVHOQ-UTONKHPSSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AzilectTablet1 mg/1OralPhysicians Total Care, Inc.2010-12-03Not applicableUs68546 0229 56 nlmimage10 402d2059
AzilectTablet0.5 mgOralTeva Pharmaceutical Industries2006-09-14Not applicableCanada
AzilectTablet.5 mg/1OralTeva Neuroscience, Inc.2006-07-10Not applicableUs68546 0142 56 nlmimage10 08130478
AzilectTablet1.0 mgOralTeva Pharmaceutical Industries2006-09-14Not applicableCanada
AzilectTablet1 mg/1OralTeva Neuroscience, Inc.2006-07-10Not applicableUs
AzilectTablet1 mg/1OralAphena Pharma Solutions Tennessee, Inc.2006-07-10Not applicableUs
RasagilineTablet.5 mg/1OralTeva2017-01-03Not applicableUs
RasagilineTablet1 mg/1OralTeva2017-01-03Not applicableUs
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rasagilineTablet0.5 mgOralApotex Corporation2016-01-12Not applicableCanada
Apo-rasagilineTablet1 mgOralApotex Corporation2016-01-12Not applicableCanada
Rasagiline MesylateTablet.5 mg/1OralMylan Pharmaceuticals2017-05-26Not applicableUs
Rasagiline MesylateTablet1 mg/1OralAlvogen, Inc.2016-12-19Not applicableUs
Rasagiline MesylateTablet1 mg/1OralMylan Pharmaceuticals2017-05-26Not applicableUs
Rasagiline MesylateTablet.5 mg/1OralAlvogen, Inc.2016-12-19Not applicableUs
Rasagiline MylanTablet1 mgOralMylan S.A.S.2016-04-04Not applicableEu
Rasagiline MylanTablet1 mgOralMylan S.A.S.2016-04-04Not applicableEu
Rasagiline MylanTablet1 mgOralMylan S.A.S.2016-04-04Not applicableEu
Rasagiline MylanTablet1 mgOralMylan S.A.S.2016-04-04Not applicableEu
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RasagilineTablet.5 mg/1OralAscend Laboratories, LLC2017-10-30Not applicableUs
RasagilineTablet1 mg/1OralAscend Laboratories, LLC2017-10-30Not applicableUs
Categories
UNII
003N66TS6T
CAS number
136236-51-6
Weight
Average: 171.2383
Monoisotopic: 171.104799421
Chemical Formula
C12H13N
InChI Key
RUOKEQAAGRXIBM-GFCCVEGCSA-N
InChI
InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
IUPAC Name
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
SMILES
C#CCN[[email protected]@H]1CCC2=CC=CC=C12

Pharmacology

Indication

For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.

Structured Indications
Pharmacodynamics

Rasagiline is a propargylamine and an irreversible inhibitor of monoamine oxidase (MAO). MAO, a flavin-containing enzyme, regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. It is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO-A is found predominantly in the GI tract and liver, and regulates the metabolic degradation of circulating catecholamines and dietary amines. MAO-B is the major form in the human brain and is responsible for the regulation of the metabolic degradation of dopamine and phenylethylamine. In ex vivo animal studies in brain, liver and intestinal tissues rasagiline was shown to be a potent,selective, and irreversible monoamine oxidase type B (MAO-B) inhibitor. At the recommended therapeutic doses, Rasagiline was also shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (and not MAO-A) in humans and the sensitivity to tyramine during rasagiline treatment at any dose has not been sufficiently characterized to avoid restriction of dietary tyramine and amines contained in medications.

Mechanism of action

The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.

TargetActionsOrganism
AAmine oxidase [flavin-containing] B
inhibitor
Human
AApoptosis regulator Bcl-2
activator
Human
Absorption

Rasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%.

Volume of distribution
  • 87 L
Protein binding

Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml.

Metabolism

Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.

Route of elimination

Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine.

Half life

Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.

Clearance
Not Available
Toxicity

Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineRasagiline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRasagiline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineRasagiline may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Rasagiline can be increased when it is combined with Abiraterone.Approved
AcarboseRasagiline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololRasagiline may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acetophenazine.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Rasagiline.Experimental
AlbiglutideRasagiline may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aldesleukin.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Rasagiline.Approved, Illicit
AliskirenRasagiline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Rasagiline.Approved, Investigational
AlogliptinRasagiline may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Rasagiline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Rasagiline.Illicit
AlprenololRasagiline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Rasagiline.Approved
AmbrisentanRasagiline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Rasagiline.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amiloride.Approved
AmineptineRasagiline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Rasagiline.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Rasagiline.Approved
AmlodipineRasagiline may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Rasagiline.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rasagiline.Approved
AmperozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amperozide.Experimental
AmphetamineRasagiline may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rasagiline.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Rasagiline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Rasagiline.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rasagiline.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rasagiline.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Asenapine.Approved
AtenololRasagiline may increase the hypotensive activities of Atenolol.Approved
AtomoxetineRasagiline may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineRasagiline may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Azaperone.Investigational, Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Rasagiline can be decreased when combined with Azithromycin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Rasagiline.Experimental
BarbitalBarbital may increase the hypotensive activities of Rasagiline.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Rasagiline.Approved
BenazeprilRasagiline may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideRasagiline may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinRasagiline may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Benperidol.Investigational
BenzphetamineRasagiline may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilRasagiline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Rasagiline.Approved
BetaxololRasagiline may increase the hypotensive activities of Betaxolol.Approved
BethanidineRasagiline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bezafibrate.Approved
BietaserpineRasagiline may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bifeprunox.Investigational
BimatoprostRasagiline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololRasagiline may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe metabolism of Rasagiline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanRasagiline may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Rasagiline may increase the hypotensive activities of BQ-123.Investigational
BretyliumRasagiline may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.Approved
BrofaromineRasagiline may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rasagiline.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bromperidol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Rasagiline.Approved, Investigational
BupranololRasagiline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline.Approved, Illicit, Investigational, Vet Approved
BupropionRasagiline may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Rasagiline.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Rasagiline.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rasagiline.Approved
CadralazineRasagiline may increase the hypotensive activities of Cadralazine.Experimental
CafedrineRasagiline may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Rasagiline can be decreased when combined with Caffeine.Approved
CanagliflozinRasagiline may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanRasagiline may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilRasagiline may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilRasagiline may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilRasagiline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rasagiline.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Rasagiline.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cariprazine.Approved
CaroxazoneRasagiline may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololRasagiline may increase the hypotensive activities of Carteolol.Approved
CarvedilolRasagiline may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololRasagiline may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideRasagiline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineRasagiline may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideRasagiline may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneRasagiline may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineRasagiline may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilRasagiline may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rasagiline.Approved, Investigational
CirazolineRasagiline may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Rasagiline.Approved
ClemastineRasagiline may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Rasagiline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Rasagiline.Approved, Vet Approved
ClonidineRasagiline may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clopenthixol.Experimental
CloranololRasagiline may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Rasagiline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Rasagiline.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Rasagiline.Approved, Investigational
CryptenamineRasagiline may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Rasagiline.Approved
CyclopenthiazideRasagiline may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideRasagiline may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineRasagiline may increase the anticholinergic activities of Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Rasagiline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinRasagiline may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.Investigational
DebrisoquinRasagiline may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilRasagiline may increase the hypotensive activities of Delapril.Experimental
DeserpidineRasagiline may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Rasagiline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Rasagiline.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateRasagiline may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineRasagiline may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanRasagiline may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Rasagiline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Rasagiline.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Rasagiline.Approved, Investigational
DiazoxideRasagiline may increase the hypotensive activities of Diazoxide.Approved
DibenzepinRasagiline may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Diclofenamide.Approved
diethylnorspermineRasagiline may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionRasagiline may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineRasagiline may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Rasagiline.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Rasagiline.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Rasagiline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Rasagiline.Experimental, Illicit
DiltiazemRasagiline may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Rasagiline.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dipyridamole.Approved
DisopyramideRasagiline may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Rasagiline.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideRasagiline may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Rasagiline can be increased when it is combined with Dosulepin.Approved
DoxapramRasagiline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinRasagiline may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Rasagiline.Approved
DoxylamineRasagiline may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Rasagiline.Investigational
DroperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Rasagiline.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droxidopa.Approved, Investigational
DulaglutideRasagiline may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineRasagiline may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Rasagiline.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ecopipam.Investigational
EfonidipineRasagiline may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Rasagiline.Approved, Investigational
EmpagliflozinRasagiline may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilRasagiline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatRasagiline may increase the hypotensive activities of Enalaprilat.Approved
EndralazineRasagiline may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.Approved, Investigational
EpanololRasagiline may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineRasagiline may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Eplerenone.Approved
EpoprostenolRasagiline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanRasagiline may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Rasagiline.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Rasagiline.Approved, Investigational
EsmirtazapineRasagiline may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Rasagiline is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Rasagiline is combined with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Rasagiline.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Rasagiline.Approved, Illicit
EtoperidoneRasagiline may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Rasagiline.Illicit, Vet Approved
ExenatideRasagiline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineRasagiline may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamRasagiline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rasagiline.Approved, Illicit, Investigational, Vet Approved
Ferulic acidRasagiline may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rasagiline.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluanisone.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rasagiline.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.Approved, Investigational
FosinoprilRasagiline may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Rasagiline.Approved, Investigational
FurazolidoneRasagiline may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Furosemide.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Rasagiline.Experimental
GliclazideRasagiline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideRasagiline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideRasagiline may increase the hypoglycemic activities of Glipizide.Approved
GlyburideRasagiline may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Rasagiline.Approved, Investigational
GuanabenzRasagiline may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelRasagiline may increase the hypotensive activities of Guanadrel.Approved
GuanazodineRasagiline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineRasagiline may increase the hypotensive activities of Guanethidine.Approved
GuanfacineRasagiline may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorRasagiline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzRasagiline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanRasagiline may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.Approved, Vet Approved
HarmalineRasagiline may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Rasagiline.Approved, Illicit, Investigational
HexamethoniumRasagiline may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Rasagiline.Approved
HydracarbazineRasagiline may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineRasagiline may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideRasagiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideRasagiline may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineRasagiline may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Rasagiline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Rasagiline.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Rasagiline.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.Approved
IndalpineRasagiline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideRasagiline may increase the hypotensive activities of Indapamide.Approved
IndenololRasagiline may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminRasagiline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartRasagiline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRasagiline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineRasagiline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineRasagiline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanRasagiline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproRasagiline may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Rasagiline.Approved
IprindoleRasagiline may increase the serotonergic activities of Iprindole.Experimental
IproclozideRasagiline may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidRasagiline may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanRasagiline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rasagiline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Rasagiline.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoxsuprine.Approved, Withdrawn
IsradipineRasagiline may increase the hypotensive activities of Isradipine.Approved
KetanserinRasagiline may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Rasagiline.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rasagiline.Approved, Nutraceutical, Withdrawn
LabetalolRasagiline may increase the hypotensive activities of Labetalol.Approved
LacidipineRasagiline may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostRasagiline may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineRasagiline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Rasagiline is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Rasagiline.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Rasagiline.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Rasagiline.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Rasagiline is combined with Levomilnacipran.Approved
LevonordefrinRasagiline may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Rasagiline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Rasagiline.Approved, Investigational
LidocaineThe metabolism of Rasagiline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Rasagiline is combined with Linezolid.Approved, Investigational
LinsidomineRasagiline may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideRasagiline may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineRasagiline may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilRasagiline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Rasagiline.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.Approved
LobeglitazoneThe metabolism of Rasagiline can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Rasagiline.Illicit
LofepramineRasagiline may increase the serotonergic activities of Lofepramine.Experimental
LofexidineRasagiline may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lorcaserin.Approved
LosartanRasagiline may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.Approved
MacitentanRasagiline may increase the hypotensive activities of Macitentan.Approved
ManidipineRasagiline may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rasagiline.Approved
MebanazineRasagiline may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineRasagiline may increase the hypotensive activities of Mecamylamine.Approved
MecaserminRasagiline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Melperone.Approved, Investigational
MephedroneRasagiline may increase the hypertensive activities of Mephedrone.Investigational
MephentermineRasagiline may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Rasagiline.Experimental
MequitazineRasagiline may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.Approved, Investigational
MetaraminolRasagiline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminRasagiline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Rasagiline.Approved, Illicit
MethamphetamineRasagiline may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Rasagiline.Approved
MethoserpidineRasagiline may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.Approved
MethoxamineRasagiline may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Rasagiline.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Rasagiline.Experimental
Methylene blueRasagiline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateRasagiline may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Rasagiline.Approved
MetipranololRasagiline may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.Approved, Investigational
MetolazoneRasagiline may increase the hypotensive activities of Metolazone.Approved
MetoprololRasagiline may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineRasagiline may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe serum concentration of Rasagiline can be increased when it is combined with Mexiletine.Approved
MianserinRasagiline may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilRasagiline may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineRasagiline may increase the hypertensive activities of Midodrine.Approved
MidomafetamineRasagiline may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Rasagiline can be increased when it is combined with Midostaurin.Approved
MifepristoneRasagiline may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolRasagiline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Rasagiline is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Rasagiline.Approved
MinoxidilRasagiline may increase the hypotensive activities of Minoxidil.Approved
MirtazapineRasagiline may increase the central neurotoxic activities of Mirtazapine.Approved
MMDARasagiline may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.Approved
MoexiprilRasagiline may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mosapramine.Experimental
MoxonidineRasagiline may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineRasagiline may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Rasagiline.Approved, Investigational
NadololRasagiline may increase the hypotensive activities of Nadolol.Approved
NaftopidilRasagiline may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Rasagiline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Rasagiline.Approved, Investigational
NateglinideRasagiline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololRasagiline may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Rasagiline.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Rasagiline can be decreased when combined with Nevirapine.Approved
NialamideRasagiline may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineRasagiline may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Rasagiline.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Nifedipine.Approved
NiguldipineRasagiline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineRasagiline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineRasagiline may increase the hypotensive activities of Nimodipine.Approved
NisoldipineRasagiline may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineRasagiline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Rasagiline.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Nitroglycerin.Approved, Investigational
NitroprussideRasagiline may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineRasagiline may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Rasagiline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Rasagiline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rasagiline.Approved
OctamoxinRasagiline may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine.Approved, Investigational
OlmesartanRasagiline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olodaterol.Approved
OmapatrilatRasagiline may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Rasagiline.Approved
OpipramolRasagiline may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Rasagiline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Rasagiline can be decreased when it is combined with Osimertinib.Approved
OxprenololRasagiline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rasagiline.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Rasagiline.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Papaverine.Approved
PargylineRasagiline may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rasagiline.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololRasagiline may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Penfluridol.Experimental
PentamidineRasagiline may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Rasagiline.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
PentoliniumRasagiline may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Rasagiline.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilRasagiline may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perphenazine.Approved
PethidineRasagiline may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Rasagiline.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rasagiline.Approved
PheniprazineRasagiline may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Rasagiline.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Rasagiline.Experimental
PhenoxybenzamineRasagiline may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineRasagiline may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineRasagiline may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineRasagiline may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineRasagiline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Rasagiline.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Rasagiline.Investigational
PimozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pimozide.Approved
PinacidilRasagiline may increase the hypotensive activities of Pinacidil.Withdrawn
PindololRasagiline may increase the hypotensive activities of Pindolol.Approved
PioglitazoneRasagiline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Rasagiline.Investigational
PirlindoleRasagiline may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineRasagiline may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenRasagiline may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorRasagiline may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideRasagiline may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rasagiline.Approved, Investigational
PramlintideRasagiline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinRasagiline may increase the hypotensive activities of Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rasagiline.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rasagiline.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Rasagiline.Approved, Investigational, Vet Approved
PropranololRasagiline may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rasagiline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Rasagiline.Investigational
PseudoephedrineRasagiline may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.Approved
QuinaprilRasagiline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineRasagiline may increase the hypoglycemic activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Raclopride.Investigational
RamiprilRasagiline may increase the hypotensive activities of Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remifentanil.Approved
RemikirenRasagiline may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.Approved, Withdrawn
RepaglinideRasagiline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineRasagiline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Reserpine.Approved, Investigational
RilmenidineRasagiline may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatRasagiline may increase the hypotensive activities of Riociguat.Approved
RisperidoneRasagiline may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ritanserin.Investigational
RitobegronRasagiline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Rasagiline.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ropivacaine.Approved
RosiglitazoneRasagiline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sacubitril.Approved
SafrazineRasagiline may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salmeterol.Approved
SaprisartanRasagiline may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinRasagiline may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Rasagiline.Approved, Investigational, Vet Approved
SelexipagRasagiline may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Rasagiline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe metabolism of Rasagiline can be decreased when combined with Simeprevir.Approved
SitagliptinRasagiline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanRasagiline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sotalol.Approved
SpiraprilRasagiline may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Rasagiline is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sufentanil.Approved, Investigational
SulfadiazineRasagiline may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleRasagiline may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleRasagiline may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Rasagiline.Approved, Investigational
SunitinibRasagiline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololRasagiline may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Rasagiline.Approved
TelmisartanRasagiline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilRasagiline may increase the hypotensive activities of Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Rasagiline can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.Approved
TerlipressinRasagiline may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Rasagiline.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Rasagiline.Approved
TetrahydropalmatineRasagiline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineRasagiline may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineRasagiline may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Rasagiline can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Rasagiline.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tiapride.Approved, Investigational
TiboloneRasagiline may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Rasagiline can be decreased when combined with Ticlopidine.Approved
TicrynafenRasagiline may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Rasagiline.Experimental
TimololRasagiline may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tizanidine.Approved
TolazamideRasagiline may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineRasagiline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideRasagiline may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.Approved, Withdrawn
TolonidineRasagiline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneRasagiline may increase the hypertensive activities of Toloxatone.Approved
TorasemideRasagiline may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Rasagiline.Approved, Investigational
TrandolaprilRasagiline may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineRasagiline may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.Approved
TravoprostRasagiline may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Rasagiline.Approved, Investigational
TreprostinilRasagiline may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triamterene.Approved
TrichlormethiazideRasagiline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.Approved, Vet Approved
TrimazosinRasagiline may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanRasagiline may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Rasagiline.Approved
TropisetronTropisetron may increase the serotonergic activities of Rasagiline.Approved, Investigational
UnoprostoneRasagiline may increase the hypotensive activities of Unoprostone.Approved
UrapidilRasagiline may increase the hypotensive activities of Urapidil.Investigational
ValsartanRasagiline may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Rasagiline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Rasagiline.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Rasagiline.Approved
VincamineRasagiline may increase the hypotensive activities of Vincamine.Experimental
VinpocetineRasagiline may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Rasagiline.Approved
XipamideRasagiline may increase the hypotensive activities of Xipamide.Experimental
XylometazolineRasagiline may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineRasagiline may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.Approved
ZofenoprilRasagiline may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Rasagiline.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Rasagiline can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol and caffeine.

References

Synthesis Reference

Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar, "Rasagiline formulations and processes for their preparation." U.S. Patent US07598420, issued October 06, 2009.

US07598420
General References
  1. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186]
External Links
Human Metabolome Database
HMDB15454
KEGG Drug
D02562
PubChem Compound
3052776
PubChem Substance
46506045
ChemSpider
2314553
BindingDB
10989
ChEBI
63620
ChEMBL
CHEMBL887
Therapeutic Targets Database
DAP001107
PharmGKB
PA164764584
HET
RAU
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Rasagiline
ATC Codes
N04BD02 — Rasagiline
AHFS Codes
  • 28:36.32 — Monoamine Oxidase B Inhibitors
PDB Entries
5g6s
FDA label
Download (200 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentParkinson's Disease (PD)4
2Active Not RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAlzheimer's Disease (AD) / Dementias1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentMultiple System Atrophy (MSA)1
2RecruitingTreatmentAlzheimer's Disease (AD)1
2Unknown StatusTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2, 3TerminatedTreatmentRestless Legs Syndrome (RLS)1
3CompletedNot AvailableParkinson's Disease (PD)1
3CompletedTreatmentParkinson's Disease (PD)10
3CompletedTreatmentParkinson´s Disease1
3Not Yet RecruitingTreatmentParkinson's Disease (PD)1
3TerminatedTreatmentIdiopathic Parkinson's Disease / Parkinson's Disease (PD)1
3TerminatedTreatmentParkinson's Disease (PD)1
3TerminatedTreatmentProgressive Supranuclear Palsy (PSP)1
4CompletedNot AvailableParkinson's Disease (PD)1
4CompletedTreatmentDepressive Symptoms / Parkinson's Disease (PD)1
4CompletedTreatmentParkinson's Disease (PD)7
4CompletedTreatmentParkinsons's Disease / Sleep Disturbances1
4CompletedTreatmentParkinson´s Disease1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingSupportive CareRetinal Detachment1
4TerminatedTreatmentEarly-Stage Parkinson's Disease1
4TerminatedTreatmentParkinson's Disease (PD)1
4Unknown StatusTreatmentApathy / Drug-naïve Patients With Parkinson's Disease1
4Unknown StatusTreatmentParkinson's Disease (PD)3
Not AvailableActive Not RecruitingNot AvailableParkinson's Disease (PD)1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)2
Not AvailableCompletedNot AvailableSerotonin Syndrome1
Not AvailableRecruitingNot AvailableParkinson's Disease (PD)1
Not AvailableRecruitingTreatmentParkinson's Disease (PD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral.5 mg/1
TabletOral0.5 mg
TabletOral1 mg/1
TabletOral1.0 mg
Prices
Unit descriptionCostUnit
Azilect 0.5 mg tablet12.11USD tablet
Azilect 1 mg tablet12.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5387612No1995-02-072012-02-07Us
CA2232310No2008-01-082016-09-18Canada
CA2031714No1998-08-252010-12-06Canada
US5453446No1997-02-072017-02-07Us
US7815942No2007-08-272027-08-27Us
US7572834No2006-12-052026-12-05Us
US6126968No1996-09-182016-09-18Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP2.26ALOGPS
logP2.3ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.47 m3·mol-1ChemAxon
Polarizability20.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9901
Blood Brain Barrier+0.9782
Caco-2 permeable+0.5585
P-glycoprotein substrateNon-substrate0.661
P-glycoprotein inhibitor INon-inhibitor0.7409
P-glycoprotein inhibitor IINon-inhibitor0.7116
Renal organic cation transporterNon-inhibitor0.5584
CYP450 2C9 substrateNon-substrate0.8037
CYP450 2D6 substrateSubstrate0.5724
CYP450 3A4 substrateNon-substrate0.6928
CYP450 1A2 substrateInhibitor0.9037
CYP450 2C9 inhibitorNon-inhibitor0.8259
CYP450 2D6 inhibitorInhibitor0.6769
CYP450 2C19 inhibitorInhibitor0.5689
CYP450 3A4 inhibitorNon-inhibitor0.8542
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.534
Ames testNon AMES toxic0.6468
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.6073
Rat acute toxicity2.8164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7804
hERG inhibition (predictor II)Non-inhibitor0.7137
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indanes
Sub Class
Not Available
Direct Parent
Indanes
Alternative Parents
Aralkylamines / Dialkylamines / Acetylides / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Indane / Aralkylamine / Acetylide / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
terminal acetylenic compound, secondary amine, indanes (CHEBI:63620)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Naoi M, Maruyama W: Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68. [PubMed:19673610]
  2. Uzun M, Alp R, Uzlu E, Alp S, Citil M, Topcu B, Erdogan HM: Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):95-8. [PubMed:19499843]
  3. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833]
  4. Chau KY, Cooper JM, Schapira AH: Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010 Nov;57(5):525-9. doi: 10.1016/j.neuint.2010.06.017. Epub 2010 Jul 17. [PubMed:20624440]
  5. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573]
  6. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. [PubMed:15573406]
  7. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484]
  8. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833]
  2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105-8. [PubMed:12057839]
  3. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82. [PubMed:12200198]
  4. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M: The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003 Oct 15;66(8):1635-41. [PubMed:14555244]
  5. Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005 Nov;19(13):1899-901. Epub 2005 Sep 7. [PubMed:16148027]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P: Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag. 2007 Jun;3(3):467-74. [PubMed:18488080]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34